Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1991 Jan;37:171–180.

Non-steroidal Anti-inflammatory Drugs

Monitoring to help prevent serious adverse effects

Barbara Cardario, Allan A McKinnon
PMCID: PMC2145121  PMID: 21234090

Abstract

Gastrointestinal, renal, hepatic, and hematological adverse effects are all associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). Some patients are particularly at risk for such problems. Preventive measures and recommendations for managing and monitoring high-risk patients are presented. Patients receiving long-term NSAID therapy should be carefully monitored.

Full text

PDF
171

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aabakken L., Osnes M. Management of NSAID-induced gastrointestinal lesions. Scand J Gastroenterol Suppl. 1988;155:106–118. doi: 10.3109/00365528809096293. [DOI] [PubMed] [Google Scholar]
  2. Abramson S., Edelson H., Kaplan H., Given W., Weissmann G. The inactivation of the polymorphonuclear leukocyte by non-steroidal anti-inflammatory drugs. Inflammation. 1984 Jun;8 (Suppl):S103–S108. doi: 10.1007/BF00915717. [DOI] [PubMed] [Google Scholar]
  3. Advenier C., Roux A., Gobert C., Massias P., Varoquaux O., Flouvat B. Pharmacokinetics of ketoprofen in the elderly. Br J Clin Pharmacol. 1983 Jul;16(1):65–70. doi: 10.1111/j.1365-2125.1983.tb02145.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Aiken J. W., Vane J. R. Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther. 1973 Mar;184(3):678–687. [PubMed] [Google Scholar]
  5. Albengres E., Pinquier J. L., Riant P., Bree F., Urien S., Barre J., Tillement J. P. Pharmacological criteria for risk-benefit evaluation of NSAIDs. Scand J Rheumatol Suppl. 1988;73:3–15. doi: 10.3109/03009748809104663. [DOI] [PubMed] [Google Scholar]
  6. Arisz L., Donker A. J., Brentjens J. R., van der Hem G. K. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand. 1976;199(1-2):121–125. doi: 10.1111/j.0954-6820.1976.tb06701.x. [DOI] [PubMed] [Google Scholar]
  7. Bartle W. R., Gupta A. K., Lazor J. Nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding. A case-control study. Arch Intern Med. 1986 Dec;146(12):2365–2367. [PubMed] [Google Scholar]
  8. Beard K., Walker A. M., Perera D. R., Jick H. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med. 1987 Sep;147(9):1621–1623. [PubMed] [Google Scholar]
  9. Berg K. J., Talseth T. Acute renal effects of sulindac and indomethacin in chronic renal failure. Clin Pharmacol Ther. 1985 Apr;37(4):447–452. doi: 10.1038/clpt.1985.69. [DOI] [PubMed] [Google Scholar]
  10. Blackshear J. L., Davidman M., Stillman M. T. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1983 Jun;143(6):1130–1134. [PubMed] [Google Scholar]
  11. Boyer T. D., Zia P., Reynolds T. B. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 1979 Aug;77(2):215–222. [PubMed] [Google Scholar]
  12. Brater D. C. Clinical aspects of renal prostaglandins and NSAID therapy. Semin Arthritis Rheum. 1988 Feb;17(3 Suppl 2):17–22. doi: 10.1016/0049-0172(88)90040-6. [DOI] [PubMed] [Google Scholar]
  13. Bulpitt C. J. Pharmaco-epidemiological considerations in patients with arthritis and vascular disease of the kidney. Scand J Rheumatol Suppl. 1986;62:4–13. doi: 10.3109/03009748609101449. [DOI] [PubMed] [Google Scholar]
  14. Butt J. H., Barthel J. S., Moore R. A. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Natural history, symptomatology, and significance. Am J Med. 1988 Feb 22;84(2A):5–14. doi: 10.1016/0002-9343(88)90248-3. [DOI] [PubMed] [Google Scholar]
  15. Caldwell J. R. Treating the elderly arthritic--the doctor's dilemma. Br J Clin Pract Suppl. 1988 Feb;58:11–18. [PubMed] [Google Scholar]
  16. Carson J. L., Strom B. L., Soper K. A., West S. L., Morse M. L. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 1987 Jan;147(1):85–88. [PubMed] [Google Scholar]
  17. Champion G. D. Therapeutic usage of the non-steroidal anti-inflammatory drugs. Med J Aust. 1988 Aug 15;149(4):203, 206-10, 212-3. doi: 10.5694/j.1326-5377.1988.tb120573.x. [DOI] [PubMed] [Google Scholar]
  18. Clive D. M., Stoff J. S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984 Mar 1;310(9):563–572. doi: 10.1056/NEJM198403013100905. [DOI] [PubMed] [Google Scholar]
  19. Coles L. S., Fries J. F., Kraines R. G., Roth S. H. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983 May;74(5):820–828. doi: 10.1016/0002-9343(83)91073-2. [DOI] [PubMed] [Google Scholar]
  20. Collier D. S., Pain J. A. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut. 1985 Apr;26(4):359–363. doi: 10.1136/gut.26.4.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Collins A. J., Davies J., Dixon S. A. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal anti-inflammatory drugs and a general population referred for endoscopy. Br J Rheumatol. 1986 Feb;25(1):50–53. doi: 10.1093/rheumatology/25.1.50. [DOI] [PubMed] [Google Scholar]
  22. Collins A. J., Du Toit J. A. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol. 1987 Aug;26(4):295–298. doi: 10.1093/rheumatology/26.4.295. [DOI] [PubMed] [Google Scholar]
  23. Day R. O., Graham G. G., Williams K. M., Champion G. D., de Jager J. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Pharmacol Ther. 1987;33(2-3):383–433. doi: 10.1016/0163-7258(87)90072-6. [DOI] [PubMed] [Google Scholar]
  24. Doube A. Liver function tests and NSAIDs in rheumatoid arthritis. N Z Med J. 1987 Feb 25;100(818):120–121. [PubMed] [Google Scholar]
  25. Dunn M. The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions. Drugs. 1987;33 (Suppl 1):56–66. doi: 10.2165/00003495-198700331-00009. [DOI] [PubMed] [Google Scholar]
  26. Goodwin J. S., Ceuppens J. L., Rodriguez M. A. Inhibition of rheumatoid factor production by non-steroidal anti-inflammatory drugs. Inflammation. 1984 Jun;8 (Suppl):S49–S55. doi: 10.1007/BF00915712. [DOI] [PubMed] [Google Scholar]
  27. Graham G. G. Pharmacokinetics and metabolism of non-steroidal anti-inflammatory drugs. Med J Aust. 1987 Dec 7;147(11-12):597–602. [PubMed] [Google Scholar]
  28. Gross P. A., Schrier R. W., Anderson R. J. Prostaglandins and water metabolism: a review with emphasis on in vivo studies. Kidney Int. 1981 Jun;19(6):839–850. doi: 10.1038/ki.1981.88. [DOI] [PubMed] [Google Scholar]
  29. Guess H. A., West R., Strand L. M., Helston D., Lydick E. G., Bergman U., Wolski K. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol. 1988;41(1):35–45. doi: 10.1016/0895-4356(88)90007-8. [DOI] [PubMed] [Google Scholar]
  30. Hogan D. L. Damage and protection of the human gastric mucosa. A multiparameter assessment. Am J Med. 1988 Feb 22;84(2A):35–40. doi: 10.1016/0002-9343(88)90252-5. [DOI] [PubMed] [Google Scholar]
  31. Hollander D., Tarnawski A., Gergely H., Zipser R. D. Sucralfate protection of the gastric mucosa against ethanol-induced injury: a prostaglandin-mediated process? Scand J Gastroenterol Suppl. 1984;101:97–102. [PubMed] [Google Scholar]
  32. Inman W. H. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J. 1977 Jun 11;1(6075):1500–1505. doi: 10.1136/bmj.1.6075.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Jick H. Effects of aspirin and acetaminophen in gastrointestinal hemorrhage. Results from the Boston Collaborative Drug Surveillance Program. Arch Intern Med. 1981 Feb 23;141(3 Spec No):316–321. doi: 10.1001/archinte.141.3.316. [DOI] [PubMed] [Google Scholar]
  34. Jiranek G. C., Kimmey M. B., Saunders D. R., Willson R. A., Shanahan W., Silverstein F. E. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):656–661. doi: 10.1016/s0016-5085(89)80062-9. [DOI] [PubMed] [Google Scholar]
  35. Kaufmann H. J., Taubin H. L. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987 Oct;107(4):513–516. doi: 10.7326/0003-4819-107-4-513. [DOI] [PubMed] [Google Scholar]
  36. Kendall M. J., Cockel R., Becker J., Hawkins C. F. Raised serum alkaline phosphatase in rheumatoid disease. An index of liver dysfunction? Ann Rheum Dis. 1970 Sep;29(5):537–540. doi: 10.1136/ard.29.5.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Kimberly R. P., Bowden R. E., Keiser H. R., Plotz P. H. Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med. 1978 May;64(5):804–807. doi: 10.1016/0002-9343(78)90520-x. [DOI] [PubMed] [Google Scholar]
  38. Kimberly R. P., Plotz P. H. Aspirin-induced depression of renal function. N Engl J Med. 1977 Feb 24;296(8):418–424. doi: 10.1056/NEJM197702242960803. [DOI] [PubMed] [Google Scholar]
  39. Kimmey M. B., Silverstein F. E. Role of H2-receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents. Am J Med. 1988 Feb 22;84(2A):49–52. doi: 10.1016/0002-9343(88)90254-9. [DOI] [PubMed] [Google Scholar]
  40. Kincaid-Smith P. Renal toxicity of non-narcotic analgesics. At-risk patients and prescribing applications. Med Toxicol. 1986;1 (Suppl 1):14–22. [PubMed] [Google Scholar]
  41. Kocsis J. J., Hernandovich J., Silver M. J., Smith J. B., Ingerman C. Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins. 1973 Feb;3(2):141–144. doi: 10.1016/0090-6980(73)90081-6. [DOI] [PubMed] [Google Scholar]
  42. Koopmans P. P., Thien T., Thomas C. M., Van den Berg R. J., Gribnau F. W. The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br J Clin Pharmacol. 1986 Apr;21(4):417–423. doi: 10.1111/j.1365-2125.1986.tb05216.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kromann-Andersen H., Pedersen A. Reported adverse reactions to and consumption of nonsteroidal anti-inflammatory drugs in Denmark over a 17-year period. Dan Med Bull. 1988 Apr;35(2):187–192. [PubMed] [Google Scholar]
  44. Ku E. C., Kothari H., Lee W., Kimble E. F., Liauw L. H. Effects of diclofenac sodium on arachidonic acid metabolism. Agents Actions Suppl. 1985;17:189–193. doi: 10.1007/978-3-0348-7720-6_23. [DOI] [PubMed] [Google Scholar]
  45. Lanza F. L. A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci. 1986 Feb;31(2 Suppl):131S–136S. doi: 10.1007/BF01309338. [DOI] [PubMed] [Google Scholar]
  46. Lanza F. L., Aspinall R. L., Swabb E. A., Davis R. E., Rack M. F., Rubin A. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 1988 Aug;95(2):289–294. doi: 10.1016/0016-5085(88)90482-9. [DOI] [PubMed] [Google Scholar]
  47. Lanza F. L., Fakouhi D., Rubin A., Davis R. E., Rack M. F., Nissen C., Geis S. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 1989 Jun;84(6):633–636. [PubMed] [Google Scholar]
  48. Lanza F. L., Royer G. L., Jr, Nelson R. S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980 Jul 17;303(3):136–138. doi: 10.1056/NEJM198007173030305. [DOI] [PubMed] [Google Scholar]
  49. Levy R. A., Smith D. L. Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients. DICP. 1989 Jan;23(1):76–85. doi: 10.1177/106002808902300122. [DOI] [PubMed] [Google Scholar]
  50. Llorca G., Larbre J. P., Collet P., Ravault A., Lejeune E. Changing the class of NSAID in cases of hepatotoxicity. Ann Rheum Dis. 1988 Sep;47(9):791–791. doi: 10.1136/ard.47.9.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Mazanec D. J. Nonsteroidal anti-inflammatory drug therapy. Clinical use in a high-risk group--the elderly. Cleve Clin J Med. 1988 Sep-Oct;55(5):419–425. doi: 10.3949/ccjm.55.5.419. [DOI] [PubMed] [Google Scholar]
  52. McVerry R. M., Lethbridge J., Martin N., Mukerjee S. K., Littler T., Tallis R., Sibeon R., Orme M. L. Pharmacokinetics of naproxen in elderly patients. Eur J Clin Pharmacol. 1986;31(4):463–468. doi: 10.1007/BF00613525. [DOI] [PubMed] [Google Scholar]
  53. Miescher P. A. Blood dyscrasias secondary to non-steroidal anti-inflammatory drugs. Med Toxicol. 1986;1 (Suppl 1):57–70. [PubMed] [Google Scholar]
  54. Miller T. A. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983 Nov;245(5 Pt 1):G601–G623. doi: 10.1152/ajpgi.1983.245.5.G601. [DOI] [PubMed] [Google Scholar]
  55. Moncada S., Ferreira S. H., Vane J. R. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature. 1973 Nov 23;246(5430):217–219. doi: 10.1038/246217a0. [DOI] [PubMed] [Google Scholar]
  56. Moore J. G., Bjorkman D. J. NSAID-induced gastropathy in the elderly: understanding and avoidance. Geriatrics. 1989 Aug;44(8):51–57. [PubMed] [Google Scholar]
  57. Muther R. S., Potter D. M., Bennett W. M. Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance. Ann Intern Med. 1981 Mar;94(3):317–321. doi: 10.7326/0003-4819-94-3-317. [DOI] [PubMed] [Google Scholar]
  58. Nesher G., Zimran A., Hershko C. Hyperkalemia associated with sulindac therapy. J Rheumatol. 1986 Dec;13(6):1084–1085. [PubMed] [Google Scholar]
  59. Netter P., Castot A., Larrey D., Carlier P., Bannwarth B., Trechot P. Hepatitis induced by non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1989 May;48(5):439–439. doi: 10.1136/ard.48.5.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Paulus H. E. FDA Arthritis Advisory Committee meeting. Arthritis Rheum. 1982 Sep;25(9):1124–1125. doi: 10.1002/art.1780250914. [DOI] [PubMed] [Google Scholar]
  61. Prescott L. F. Liver damage with non-narcotic analgesics. Med Toxicol. 1986;1 (Suppl 1):44–56. [PubMed] [Google Scholar]
  62. Quintero E., Ginés P., Arroyo V., Rimola A., Camps J., Gaya J., Guevara A., Rodamilans M., Rodés J. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron. 1986;42(4):298–303. doi: 10.1159/000183692. [DOI] [PubMed] [Google Scholar]
  63. Rachmilewitz D., Ligumsky M., Fich A., Goldin E., Eliakim A., Karmeli F. Role of endogenous gastric prostanoids in the pathogenesis and therapy of duodenal ulcer. Gastroenterology. 1986 Apr;90(4):963–969. doi: 10.1016/0016-5085(86)90874-7. [DOI] [PubMed] [Google Scholar]
  64. Roberts D. G., Gerber J. G., Barnes J. S., Zerbe G. O., Nies A. S. Sulindac is not renal sparing in man. Clin Pharmacol Ther. 1985 Sep;38(3):258–265. doi: 10.1038/clpt.1985.168. [DOI] [PubMed] [Google Scholar]
  65. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Roth S. H., Bennett R. E. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med. 1987 Dec;147(12):2093–2100. [PubMed] [Google Scholar]
  67. Sack K. E. Update on NSAIDS in the elderly. Geriatrics. 1989 May;44(5):71-5, 79-80, 89-90. [PubMed] [Google Scholar]
  68. Schlegel S. I., Paulus H. E. Non-steroidal and analgesic therapy in the elderly. Clin Rheum Dis. 1986 Apr;12(1):245–273. [PubMed] [Google Scholar]
  69. Seaman W. E., Ishak K. G., Plotz P. H. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med. 1974 Jan;80(1):1–8. doi: 10.7326/0003-4819-80-1-1. [DOI] [PubMed] [Google Scholar]
  70. Semble E. L., Turner R. A., Wu W. C. Clinical and genetic characteristics of upper gastrointestinal disease in rheumatoid arthritis. J Rheumatol. 1987 Aug;14(4):692–699. [PubMed] [Google Scholar]
  71. Silvoso G. R., Ivey K. J., Butt J. H., Lockard O. O., Holt S. D., Sisk C., Baskin W. N., Mackercher P. A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520. doi: 10.7326/0003-4819-91-4-517. [DOI] [PubMed] [Google Scholar]
  72. Skander M. P., Ryan F. P. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. BMJ. 1988 Oct 1;297(6652):833–834. doi: 10.1136/bmj.297.6652.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sladen G. Peptic ulcer, nonsteroid anti-inflammatory drugs and the rheumatic diseases. Br J Rheumatol. 1986 Nov;25(4):330–332. doi: 10.1093/rheumatology/25.4.330. [DOI] [PubMed] [Google Scholar]
  74. Stafanger G., Larsen H. W., Hansen H., Serensen K. Pharmacocinétique du kétoprofène chez l'insuffisant rénal. Sem Hop. 1983 Dec 12;59(46):3191–3193. [PubMed] [Google Scholar]
  75. Storti E., Molinari E. Blood disorders secondary to the use of non-steroidal anti-inflammatory drugs. Haematologica. 1988 May-Jun;73(3):239–243. [PubMed] [Google Scholar]
  76. Sun D. C., Roth S. H., Mitchell C. S., Englund D. W. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis. 1974 May;19(5):405–410. doi: 10.1007/BF01255603. [DOI] [PubMed] [Google Scholar]
  77. Svendsen U. G., Gerstoft J., Hansen T. M., Christensen P., Lorenzen I. The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure. J Rheumatol. 1984 Dec;11(6):779–782. [PubMed] [Google Scholar]
  78. Szabo S., Pihan G. Mechanisms of gastric cytoprotection. J Clin Gastroenterol. 1987;9 (Suppl 1):8–13. doi: 10.1097/00004836-198709011-00003. [DOI] [PubMed] [Google Scholar]
  79. Tesler M. A., Lim E. S. Protection of gastric mucosa by sucralfate from aspirin-induced erosions. J Clin Gastroenterol. 1981;3(Suppl 2):175–179. [PubMed] [Google Scholar]
  80. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  81. Vane J. The evolution of non-steroidal anti-inflammatory drugs and their mechanisms of action. Drugs. 1987;33 (Suppl 1):18–27. doi: 10.2165/00003495-198700331-00005. [DOI] [PubMed] [Google Scholar]
  82. Verbeeck R., Tjandramaga T. B., Mullie A., Verbesselt R., Verberckmoes R., de Schepper P. J. Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency. Br J Clin Pharmacol. 1979 Mar;7(3):273–282. doi: 10.1111/j.1365-2125.1979.tb00932.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Weiss H. J., Aledort L. M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968 Sep;47(9):2169–2180. doi: 10.1172/JCI105903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Wilkinson G. R. Drug distribution and renal excretion in the elderly. J Chronic Dis. 1983;36(1):91–102. doi: 10.1016/0021-9681(83)90048-6. [DOI] [PubMed] [Google Scholar]
  85. Woodhouse K. W., Wynne H. The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet. 1987 Feb;12(2):111–122. doi: 10.2165/00003088-198712020-00002. [DOI] [PubMed] [Google Scholar]
  86. Zimran A., Kramer M., Plaskin M., Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed) 1985 Jul 13;291(6488):107–108. doi: 10.1136/bmj.291.6488.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Zipser R. D., Hoefs J. C., Speckart P. F., Zia P. K., Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979 Jun;48(6):895–900. doi: 10.1210/jcem-48-6-895. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES